Integra LifeSciences(IART) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline [15] - Fourth quarter revenues were $435 million, reflecting a decrease of 1.7% on a reported basis and an organic decline of 2.5% [17] - Full-year gross margin was 61.9%, down 260 basis points year-over-year, while adjusted EBITDA margin was 19.4%, down 60 basis points [16] - Adjusted EPS for the full year was $2.23, compared to $2.56 in 2024 [16] Business Line Data and Key Metrics Changes - In the global neurosurgery segment, organic growth was 1.4%, with double-digit growth in CereLink, MAYFIELD Capital, and AURORA [18] - Tissue Technologies revenues were $111.6 million, down 12.8% on both a reported and organic basis, with a 21.4% decline in the Wound Reconstruction franchise [19] - The capital business grew in the low double digits, while instruments posted low single-digit growth [18] Market Data and Key Metrics Changes - International markets contributed to high single-digit growth in the CSF business, led by double-digit performance in China and Canada [18] - Demand indicators across global markets remain strong, despite challenges in specific segments [18] Company Strategy and Development Direction - The company is focused on four strategic imperatives: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [10] - A new operating model has been implemented to reduce complexity and improve efficiency, with a focus on quality and supply chain reliability [10] - The company aims to return key products to the market and recapture share while investing in innovation and portfolio prioritization [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth and value creation prospects, despite uncertainties related to recent tariff changes [13] - The company expects improved cash flow in 2026, with operating cash flow projected to exceed $200 million [32] - Management remains cautious about organic growth due to supply constraints but sees strong underlying demand across the portfolio [40] Other Important Information - The company is actively monitoring the impact of new tariffs following a Supreme Court ruling, which may affect future financial guidance [25] - The Braintree manufacturing facility is expected to be operational by the end of June 2026, supporting the return of SurgiMend to the market [11] Q&A Session Summary Question: Free cash flow generation and improvement - Management noted that negative free cash flow was driven by timing of collections and restructuring costs, but expects significant improvement in 2026 [31] Question: Tissue Technologies business and CMS changes - Management indicated that reimbursement changes are being monitored, with no expected negative impact on business due to pricing being within new reimbursement ranges [33] Question: Growth assumptions for CSS and Tissue Tech - Management expects low single-digit growth for CSS and low to mid single-digit growth for Tissue Tech in 2026, reflecting supply constraints rather than demand issues [40] Question: Status of MediHoney remediation efforts - Management confirmed that no revenues from MediHoney are accounted for in 2026 guidance, as remediation efforts continue [51] Question: Outlook for PriMatrix and DuraRepair - Early reception for PriMatrix and DuraRepair post-relaunch has been positive, with expectations for strong contributions in 2026 [48]